| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8524733 | TEVA BRANDED PHARM | Benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Apr, 2031
(7 years from now) | |
| US9550780 | TEVA BRANDED PHARM | Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Sep, 2033
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8524733 (Pediatric) | TEVA BRANDED PHARM | Benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Oct, 2031
(8 years from now) | |
| US11666566 | TEVA BRANDED PHARM | Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Sep, 2033
(9 years from now) | |
| US9814708 | TEVA BRANDED PHARM | Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Sep, 2033
(9 years from now) | |
| US9296739 | TEVA BRANDED PHARM | Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Sep, 2033
(9 years from now) | |
| US9233959 | TEVA BRANDED PHARM | Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Sep, 2033
(9 years from now) | |
|
US9550780 (Pediatric) | TEVA BRANDED PHARM | Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Mar, 2034
(10 years from now) | |
|
US9233959 (Pediatric) | TEVA BRANDED PHARM | Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Mar, 2034
(10 years from now) | |
|
US9814708 (Pediatric) | TEVA BRANDED PHARM | Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Mar, 2034
(10 years from now) | |
|
US9296739 (Pediatric) | TEVA BRANDED PHARM | Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Mar, 2034
(10 years from now) | |
| US10959996 | TEVA BRANDED PHARM | Methods for the treatment of abnormal involuntary movement disorders |
Mar, 2036
(12 years from now) | |
| US11446291 | TEVA BRANDED PHARM | Methods for the treatment of abnormal involuntary movement disorders |
Mar, 2036
(12 years from now) | |
| US11564917 | TEVA BRANDED PHARM | Methods for the treatment of abnormal involuntary movement disorders |
Mar, 2036
(12 years from now) | |
| US11648244 | TEVA BRANDED PHARM | Methods for the treatment of abnormal involuntary movement disorders |
Mar, 2036
(12 years from now) | |
| US11357772 | TEVA BRANDED PHARM | Methods for the treatment of abnormal involuntary movement disorders |
Mar, 2036
(12 years from now) | |
|
US11648244 (Pediatric) | TEVA BRANDED PHARM | Methods for the treatment of abnormal involuntary movement disorders |
Sep, 2036
(12 years from now) | |
|
US10959996 (Pediatric) | TEVA BRANDED PHARM | Methods for the treatment of abnormal involuntary movement disorders |
Sep, 2036
(12 years from now) | |
|
US11446291 (Pediatric) | TEVA BRANDED PHARM | Methods for the treatment of abnormal involuntary movement disorders |
Sep, 2036
(12 years from now) | |
|
US11357772 (Pediatric) | TEVA BRANDED PHARM | Methods for the treatment of abnormal involuntary movement disorders |
Sep, 2036
(12 years from now) | |
|
US11564917 (Pediatric) | TEVA BRANDED PHARM | Methods for the treatment of abnormal involuntary movement disorders |
Sep, 2036
(12 years from now) | |
| US11179386 | TEVA BRANDED PHARM | Analogs of deutetrabenazine, their preparation and use |
Mar, 2038
(14 years from now) | |
|
US11179386 (Pediatric) | TEVA BRANDED PHARM | Analogs of deutetrabenazine, their preparation and use |
Sep, 2038
(14 years from now) | |
Austedo is owned by Teva Branded Pharm.
Austedo contains Deutetrabenazine.
Austedo has a total of 23 drug patents out of which 0 drug patents have expired.
Austedo was authorised for market use on 03 April, 2017.
Austedo is available in tablet;oral dosage forms.
Austedo can be used as treatment of tardive dyskinesia, treatment of tardive dyskinesia; a method of treating huntington's chorea, a method of treating huntington's chorea.
The generics of Austedo are possible to be released after 15 September, 2038.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Apr 3, 2024 |
| M (M) | Jun 24, 2024 |
| Pediatric Exclusivity (PED) | Dec 24, 2024 |
Drugs and Companies using DEUTETRABENAZINE ingredient
Market Authorisation Date: 03 April, 2017
Treatment: A method of treating huntington's chorea; Treatment of tardive dyskinesia
Dosage: TABLET;ORAL
AUSTEDO family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic